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In-vivo anterior segment oct 
imaging provides unique insight 
into cerulean blue-dot opacities and 
cataracts in Down syndrome
Julie-Anne Little1 ✉, Aman-Deep S. Mahil1, patrick Richardson1, J. Margaret Woodhouse2, 
Valldeflors Vinuela-navarro2,3 & Kathryn J. Saunders1
Down syndrome (DS) is frequently associated with cataract, but there remains scant information about 
DS cataract morphology. Supra-nuclear cataracts in DS have been proposed as indicative of beta-
amyloid (Aβ) aggregation and thus potential biomarkers for Alzheimer’s (AD). this study employed 
anterior segment oct (AS-oct) and slit-lamp (SL) photography to image the crystalline lens in DS, 
compared with adult controls. Lens images were obtained post-dilation. Using MAtLAB, AS-oct 
images were analysed and lens opacities calculated as pixel intensity and area ratios. SL images were 
classified using LOCS III. Subjects were n = 28 DS (mean ± SD 24.1 ± 14.3years), and n = 36 controls 
(54.0 ± 3.4years). For the DS group, AS-OCT imaging revealed the frequent presence of small dot 
opacities (27 eyes, 50%) in the cortex and nucleus of the lens, covering an area ranging from 0.2–14%. 
there was no relation with age or visual acuity and these dot opacities (p > 0.5) and they were not 
present in any control lenses. However, their location and morphology does not coincide with previous 
reports linking these opacities with Aβ accumulation and AD. Four participants (14%) in the DS group 
had clinically significant age-related cataracts, but there was no evidence of early onset of age-related 
cataracts in DS.
Down syndrome, caused by a full or partial copy of the 21st chromosome, is the most common chromosomal 
aneuploidy in humans1. Individuals with DS have an increased prevalence of ocular sequalae, including refractive 
errors, poor vision, strabismus, keratoconus and cataract2–13. Life expectancy for those with Down syndrome has 
significantly increased in recent decades, and thus management of age-related chronic healthcare conditions is 
ever more important14. Cataract is the most common age-related ocular disease, and is reported with increased 
frequency in DS. Prevalence rates for cataract in DS vary greatly from 4–72% depending on the profile of the 
cohort assessed8–13. Previous reports have often recruited participants from institutionalised or clinical popula-
tions and have utilised a variety of methods to examine the crystalline lens; ranging from a cursory, undilated 
examination to more in-depth mydriatic assessments. The age of participants has also varied across studies and 
there is scant published information describing the features of cataract found in Down syndrome, particularly 
the aetiology and type of cataracts. Congenital cataract is reported in 1.4% cases with DS15, while other reports 
identify cataracts similar to those seen in the ageing eye.
Due to the triplicate of chromosome 21 and subsequent overexpression of the amyloid precursor protein, 
Down syndrome is associated with increased risk of Alzheimer’s disease (AD). Senile Aβ plaques and neurofibril-
lary tangles in the brain of DS adults aged 35 to 40 years and older have been reported16,17. Zana et al.16 report the 
rates of dementia in Down syndrome at 8%, 55% and 75% in those aged 35–49, 50–59 and over 60 years respec-
tively. Clinical diagnosis of AD often relies on communication and an assessment of a patient’s ability to perform 
cognitive tests. Thus, while AD diagnosis is complex in typically developed adults, it poses even greater challenges 
in those with a learning disability. There is a need for alternative, objective and non-invasive methods of detect-
ing the presence of AD. It has been proposed that supra-nuclear cataracts in DS are indicative of beta-amyloid 
aggregation and thus could be a biomarker for Alzheimer’s disease18,19. However, given the minimal information 
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currently available regarding the morphology and frequency of cataract in DS, particularly in non-clinical DS 
populations, a better understanding of its prevalence, severity and morphology is required.
Slit lamp examination is the conventional method used to examine cataract and SL photography enables 
photograding of images. LOCS III is the most commonly used classification system for age-related cataract 
and requires optic section and retro-illumined images of the crystalline lens. However, anterior segment ocu-
lar coherence tomography (AS-OCT) is emerging as an alternative means of examining cataract. This technol-
ogy uses infra-red light to deliver cross-sectional structural imaging of the lens, and lens opacities appear as 
hyper-reflective surfaces20. Good agreement has recently been reported between traditional methods of visual-
ising cataractous changes and OCT imaging of the lens. AS-OCT also offers the opportunity to accurately exam-
ine the structure of the lens, as, unlike photographic optic sections on SL, where the angle of observation can vary, 
AS-OCT imaging is centred on the visual axis. AS-OCT also allows quantification of the location and extent of 
lens opacities through image analysis21,22.
The present study will investigate the morphology of cataract in a non-ophthalmological sample of partici-
pants with DS, and explore the feasibility of utilising SL examination, SL photography and AS-OCT imaging for 
examining the DS lens.
Results
From the 30 participants recruited with DS, two participants were excluded during preliminary testing: one due 
to a recent brain tumour diagnosis and the other because it was not possible to position their wheelchair appro-
priately for imaging assessment. Attempts were made to image both eyes of all participants, however, in two 
participants one eye was excluded due to the presence of a uniocular corneal degenerative disease with neo-
vascularisation, and a significant esotropia with poor fixation. Accordingly, SL examination and imaging of 54 
eyes from 28 participants with DS were conducted. The mean age of participants was 24.10 ± 14.20 (standard 
deviation, SD) with a range of 6 to 55 years, and 17 participants were male. Dilated pupil diameter was measured 
at 8–9 mm for all participants.
SL examination was successfully completed in 96% (n = 52) DS and 100% of control eyes. Optic section SL 
imaging was successfully obtained in 39 (72%) DS and all control eyes. Retroillumination SL images were more 
difficult to capture in the DS group and the success rate dropped to 28% (n = 15). AS-OCT images were obtained 
from 33 (61%) DS and 46 (82%) control eyes. Table 1 presents data from LOCS III photograding, AS-OCT image 
analysis, and visual acuity of participants.
In the DS group, using LOCS IIII photograding, four eyes from four individuals (14.3%) had clinically signifi-
cant age-related cataracts (n = 1 cortical, n = 2 posterior sub-capsular, n = 1 nuclear sclerotic). These were seen on 
SL examination, and all were successfully imaged for photograding. Clinically significant cataracts were defined 
as a LOCS III score23,24 of Cortical (C) >/ = 2.0, Posterior sub-capsular (P) >/ = 2.0 and Nuclear Colour (NC) 
or Nuclear Opalescence (NO) >/ = 2.5. Six control eyes presented with significant nuclear cataract, and cortical 
cataract was identified in one control eye (n = 7 individuals, 19.4%).
Comparing all LOCS III values, the control group had significantly greater amounts of NO and NC com-
pared to the DS group (z = −7.4, p < 0.00001, and z = −7.1, p < 0.00001 respectively). Conversely, the DS group 
demonstrated greater magnitude of C and P LOCS III scores compared to controls (z = 6.1, p < 0.00001, and 
z = 2.8, p < 0.006 respectively).
For the AS-OCT quantification of lens opacities by pixel intensity and pixel area ratios, Table 1 summarises 
the values for both study groups. Note that none of the control participants displayed quantifiable evidence of 
DS Controls Statistical 
comparison 
between groupsMean (+/−SD) Median (IQR) Range Mean (+/−SD) Median (IQR) Range
LOCS III grading
Nuclear Opalescence 
(NO) 0.50 (+/−0.49) 0.40 (0.40) 0.1 to 2.2 1.83 (+/−0.34) 1.80 (0.40) 1.2 to 2.7
z = −7.4, 
p < 0.00001
Nuclear Colour (NC) 0.48 (+/−0.58) 0.30 (0.40) 0.1 to 2.5 1.69 (+/−0.45) 1.75 (0.70) 0.5 to 2.5 z = −7.1, p < 0.00001
Cortical (C) 0.75 (+/−0.71) 0.50 (0.70) 0.1 to 2.4 0.17 (+/−0.37) 0.10 (0.00) 0.1 to 2.6 z = 6.1, p < 0.00001
Posterior subcapsular 
(P) 0.38 (+/−0.74) 0.10 (0.00) 0.1 to 2.3 0.10 (+/−0.00) 0.10 (0.00) 0.1 to 0.1 z = 2.8, p < 0.006
AS-OCT 
quantification of 
lens opacities
Nuclear PIR 1.19 (+/−0.06) 1.19 (0.7) 1.10 to 1.45 1.25 (+/−0.04) 1.24 (0.06) 1.18 to 1.35
z = −4.8, 
p < 0.0001
Cortical PIR 0.09 (+/−0.34) 0.0 (0.0) 0 to 1.46 0.0 (0.0) 0.0 (0.0) —
Cortical PAR 0.006 (+/−0.03) 0.0 (0.0) 0 to 0.15 0.0 (0.0) 0.0 (0.0) —
Posterior subcapsular 
PIR 0.09 (+/−0.35) 0.0 (0.0) 0 to 1.56 0.0 (0.0) 0.0 (0.0) —
Posterior subcapsular 
PAR 0.01 (+/−0.05) 0.0 (0.0) 0 to 0.24 0.0 (0.0) 0.0 (0.0) —
Visual Acuity 0.371 (+/−0.215) 0.300 (0.275) 0.050 to 0.800 −0.053 (+/−0.123) −0.080 (0.155) −0.20 to 0.38
Table 1. LOCS III grading and AS-OCT quantification of lens opacities and for DS and control groups. Pixel 
intensity ratios (PIR) and pixel area ratios (PAR) describe the brightness and extent of any lens changes. Visual 
Acuity of DS and control participants (LogMAR).
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posterior sub-capsular or cortical changes. Therefore, statistical analysis was conducted only for nuclear PIR. 
Participants with DS had significantly lower nuclear PIR compared to controls.
Comparing LOCS III NO and NC grading with AS-OCT quantification of Nuclear PIR there was a significant 
relation for both DS and control groups (Spearman rank analysis, NO: DS group ρ = 0.36, p = 0.04; Control group 
ρ = 0.42, p = 0.004. NC: DS group ρ = 0.44, p = 0.01; Control group ρ = 0.43, p = 0.003).
There was a significant relation between age and nuclear PIR for the DS group (ρ = 0.67, p < 0.00001), though 
this was not apparent for controls (ρ = 0.28, p = 0.06), likely due to the constrained recruitment age.
In the DS group, SL examination and SL and OCT imaging revealed the frequent presence of small dot opac-
ities scattered anteriorly and posteriorly through the cortex of the lens, and occasionally the nucleus. These were 
distinct from age-related changes. Figure 1 illustrates three subjects classified with ‘frequent’, ‘moderate’ and ‘few’ 
dot opacities.
There were occasions when assessing DS eyes where dot opacities were noted on SL examination but could 
not be successfully imaged using either SL or AS-OCT due to difficulties with patient fixation or alignment. 
Twenty-two lenses had visible dot opacities on either LOCS III or OCT images, with a further five in which the 
researcher noted the presence of at least one dot opacity on SL examination. Thus, in total, 27 eyes of 54 examined 
eyes presented with cortical dot opacities (50%) in those with DS. The intensity of these dot opacities was sig-
nificantly brighter than the intensity of nuclear PIR (p < 0.001), and dot opacities covered an area ranging from 
0.2–14% of the cortex (Table 2, OCT image analysis). With regard to location, there was a diffuse spread of dot 
opacities throughout the cortex, with 53.2% of dots located beyond the central 4 mm of the lens.
Monocular visual acuity measures with habitual refractive correction were successfully achieved from 94% of 
the DS group and 100% of control participants (Table 1). Neither Dot PIR nor Dot PAR values were significantly 
related to DS participant’s visual acuity or age (Mann Whitney, p > 0.5). Figure 2 is a scatterplot of number of dot 
opacities (from OCT imaging) compared with age of participants with DS.
Discussion
The current study provides the most detailed evaluation of cataract in Down syndrome to date. Some degree of 
lens opacity was seen in approximately half (54%) of DS eyes, but in only four individuals (7% eyes, 14% of DS 
participants) were these opacities classified as clinically significant ‘age-related’ cataract.
Punctate dot opacities, characteristic of developmental cerulean blue-dot type cataracts, were seen in 50% of 
DS lenses. AS-OCT imaging offers the means of quantifying these deficits, through identification and calcula-
tion of the size and pixel intensity of individual opacities. Dot PAR calculation demonstrated that dot opacities 
Figure 1. SL and AS-OCT images from three subjects with DS classified with ‘frequent’ (Panel A), ‘moderate’ 
(Panel B) and ‘few’ (Panel C) dot opacities. Individual LOCS III and PIR/PAR scores are given for each subject. 
Anterior and posterior lens AS-OCT images were aligned together to present the whole lens.
DS group Mean (+/−SD) Median (IQR) Range
Dot PIR 1.33 (+/−0.12) 1.3 (0.12) 1.14 to 1.68
Dot PAR 0.04 (+/−0.05) 0.02 (0.07) 0.004 to 0.14
Number of dots 15.63 (+/−15.87) 9 (25.25) 1 to 50
Number of 
dots in central 
4–4.5 mm
7.31 (+/−8.05) 2 (13.25) 0 to 23
Table 2. Profile of Dot opacities on OCT imaging of DS lenses (n = 16), graded by Pixel intensity ratio (PIR) 
and area ratio (PAR).
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covered an area ranging from 0.2–14% of the cortex of the DS lenses in which they were found. The opacities were 
not detrimental to visual acuity measures, nor were they related to age, but they are intriguing given the possibil-
ity that the lens in DS is a potential site for beta-amyloid accumulation.
Goldstein et al.18 reported, through post-mortem immunohistochemical analysis, that Aβ was present in 
lenses with a specific type of cataract located in the supranuclear area in individuals with Alzheimer’s disease. 
This work was developed by Moncaster et al.19 who reported supranuclear cataract in post-mortem lenses from 
individuals with DS. Supranuclear cataract is defined as a narrow band of opacity found at the interface between 
the deep cortex and nuclear interface, and is sometimes referred to as lamellar or zonular25. However, the location 
of the cerulean-type dot opacities found in the present study ranged from close to (and occasionally within) the 
nucleus to the outer cortex area; they were not confined to the ‘supra-nuclear’ region of the crystalline lens. In 
this in-vivo examination, dot opacities were scattered relatively evenly around the nucleus, with a slightly greater 
proportion in the periphery. Their presence could easily be missed without pupil dilation. The present investi-
gation found no association between the presence and number of dot opacities in the lens and age of the partic-
ipant; a finding which is counterintuitive if these dot opacities are indicative of AD (as suggested by Goldstein 
and colleagues), in a population where prevalence and risk of AD greatly increase with age. Given the findings 
of the present study and later studies of post-mortem lenses using similar techniques to Goldstein et al.18 and 
Moncaster et al.19 which failed to demonstrate presence of Aβ in the human crystalline lens26–28, it seems likely 
that the relation between cerulean cataract and Aβ found by Goldstein et al.18 and Moncaster et al.19 may have 
been an artefact, reflective of small sample sizes. Further support for the notion that dot opacities are unlikely to 
be a useful indicator of AD comes from the failure to find supranuclear cataracts in an in-vivo analysis of cataract 
in participants with AD by Bei et al.29.
The present study found no evidence that individuals with DS have earlier ‘age-related’ nuclear lens changes 
compared with the typically ageing eye. Only three DS participants had NO or NC grades over 1.0, and they 
were 55.4, 53.9 and 54.7 years of age. These participants were all in the same age bracket as our control group and 
their LOCS III nuclear grades fit within the normal range of the control group’s distributions. When comparing 
AS-OCT nuclear PIR values between the DS and control groups, the results were similar to LOCS III classifica-
tion, demonstrating significantly lower nuclear PIR in the DS compared to control group.
When compared to the literature describing the prevalence of crystalline lens opacities in DS, the present 
study identifies opacity in 54% of the 54 eyes: previous studies have reported prevalence ranging from 4–72%8–13. 
Studies reporting low levels of lens opacity were primarily conducted in children and adolescents and this finding 
chimes with the present study in which all participants under 12 years of age (where imaging was possible, n = 5) 
had clear lenses.
Considering previous studies of adult DS eyes, our findings are similar to those reported by Jaeger8 who 
undertook SL examination of the eyes of 74 participants with DS aged 15 to 64 years, and found 55.4% to have the 
presence of lens opacities. Of these opacities, the majority (65.8%) were described as ‘flake-like’ opacities, with 
18.9% of DS participants (average age 48 years) exhibiting age-related cataract8. More recently Fong et at.10 exam-
ined 91 adults with DS aged from 30 to 56 years, and report that 72% of participants presented with lens opacities. 
Of those opacities, 50.6% were described as blue-dot cataract and 45% described as ‘age-related’ (38% nuclear, 
13.6% cortical and 8.5% PSC). These prevalence rates align quite well with those found in this study.
The flake-like and blue-dot opacities that are reported at high prevalence by Jaeger8 and Fong et al.10 appear 
to be of the same morphology as the dot opacities imaged in this study. Cerulean blue-dot cataract is an acquired 
early onset lens opacity that is often noticed first in adolescence and consists of blue or white coloured opacities 
scattered primarily in the cortex but also in the nucleus of the crystalline lens30,31.
AS-OCT imaging offers a useful way to image the crystalline lens in DS and was a more successful method to 
capture images of the lens than SL photography. Furthermore, the OCT images have provided a unique insight 
Figure 2. Scatterplot of total number of dot opacities (from AS-OCT imaging) compared with the age profile of 
participants with DS.
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into the typical location of cerulean blue-dot opacity within the DS crystalline lens. As a result, the present study 
has shown that cerulean cataract occurs commonly in DS, but the location and morphology of this cataract does 
not appear to coincide with the description by studies linking it with Aβ and AD.
In common with other studies recruiting individuals with Down syndrome, it is difficult to generate a large 
sample size, and reduced success rates in acquiring adequate quality images of the crystalline lens. However, the 
study was successful in recruiting across a broad age range and older participants with DS. Advances in OCT 
technology, especially with the newest swept-source whole eye imaging capability, will provide an excellent plat-
form for studying opacity in the entire lens, enabling quantification of opacities with greater precision. Further 
work investigating cataract in Down syndrome in longitudinal studies would be valuable to understand the devel-
opment of cerulean blue-dot cataracts and what, if any, relevance their presence or absence has for the individual 
with Down syndrome.
Methods
The study received ethical approval from the NHS Office for Research Ethics Committees in Northern Ireland 
and Wales, UK. All methods were carried out in accordance with relevant guidelines and regulations. Thirty 
participants with Down syndrome between the ages of 6 and 60 years were recruited from regional day cen-
tres, family support groups, and the optometry clinics of Ulster and Cardiff Universities. Parental consent was 
obtained for children to participate and either the adult with DS consented or if this was not possible, their assent 
was recorded and written consent obtained from their carer. Exclusion criteria were previous cataract surgery, 
nystagmus, ocular albinism, keratoconus, and other significant corneal pathology that would affect imaging of 
the crystalline lens. A group of adults aged 50–60 years acted as a control group. This age range was chosen to 
uncover age-related lens changes, but not to over-represent cataract liable to be found in adults >60 years: from 
prior literature, the authors considered this to be reflective of the likely status of the DS lens. 36 participants (56 
eyes) were recruited through the local population and staff at Ulster and Cardiff Universities.
Participants visited the Centre for Optometry and Vision Sciences at Ulster and Cardiff Universities on one 
occasion for assessment with a single researcher, who was also a registered optometrist. Clinical history was taken 
to ensure inclusion and exclusion criteria were met. Referral to the appropriate care provider was organised if 
clinically significant ocular findings were revealed in the course of examination. Visual acuity was measured prior 
to dilation (with habitual refractive correction worn) using Keeler crowded LogMAR letter charts, or the crowded 
Lea symbols if letter optotype testing was not possible. Pupil dilation was achieved with 1.0% tropicamide and 
intraocular pressure was measured with the ICare tonometer (ICare, Finland) pre- and post-dilation as a signif-
icant increase would indicate an adverse event of angle-closure glaucoma requiring medical intervention. Pupil 
diameter was also measured after maximal dilation had occurred. Crystalline lens images were obtained using a 
Nikon D3000 camera mounted onto a Nikon FS-3 Slit lamp (SL) and a Zeiss Visante anterior segment OCT (Carl 
Zeiss Meditec) in that order.
Crystalline lens examination and imaging was undertaken in a dark room using the modified Nikon FS-3 
slit-lamp: attempts were made to capture multiple optic sections and retroillumination images attempted for all 
crystalline lenses. Camera and illumination settings were kept constant and in accordance with LOCS III proto-
col. When imaging cortical and PSC opacities, slit lamp settings were varied to obtain optimum retroillumination, 
again, in accordance with LOCS III protocol.
LOCS III photograding of SL images was conducted for Nuclear Opalescence (NO), nuclear colour (NC), 
cortical (C) and posterior sub-capsular (P) cataract types. After training on LOCS III system, photograding was 
conducted by a single examiner (AM). Agreement in scoring was evaluated for 10% of images with a second 
examiner (JAL) and revealed excellent agreement, with less than a 0.1 LOCS III score of bias for all measures of 
opacification. Images were graded using the same computer terminal and monitor with uniform brightness and 
colour settings, and a lightbox placed beside monitor was used for LOCS III transparencies. A grade between 0.1 
(representing complete nuclear transparency) and 6.9 was assigned for NO and NC. In accordance with instruc-
tions, care was taken to grade NO based strictly by examining the hazy quality of the nucleus without respect to 
its brunescence. For NC evaluation, the haziness of the nucleus was ignored and a grade was assigned based upon 
the brunescence reflected from of the posterior capsule. For C and P opacities, the grader considered all areas of 
opacification solely as an aggregate to determine values for C and P ranging from 0.1 to 5.9. Opacity was consid-
ered to be a true PSC only if it was located in the central 3 mm of the lens.
Visante AS-OCT lens images were captured in raw image high-resolution mode, and separate B-Scans of the 
anterior and posterior lens were acquired. Alignment was determined with the corneal reflex and B-scans were 
taken at a 90-degree orientation. If participants’ lids interfered with imaging due to narrow palpebral aperture, 
180-degree B-scans were also acquired. If necessary, additional B-scans were captured at any other axial orien-
tation in order to image lens opacities observed during slit-lamp imaging; this ensured all lens opacities were 
captured with AS-OCT imaging. Finally, an image of the whole lens was also captured with the OCT instrument’s 
low-resolution mode where possible.
Raw OCT images were processed in MATLAB (MathWorks Inc., USA) and opacities analysed by calculating 
pixel intensity ratios (PIR) for nuclear lens areas, and pixel intensity and area ratios (PAR) for cortex and PSC lens 
areas (see Fig. 3).
Raw detector data were exported for all scans using the Visante Image Exporter software (Carl Zeiss Meditec, 
Germany). The sensor data were then processed, segmented and analysed for opacity with MATLAB using cus-
tomised, bespoke software. The image was read as a 512 × 512 matrix and resized to the manufacturer’s rec-
ommended 512 × 1280 resolution using bicubic interpolation as described by Kao et al.32 Segmentation of the 
lens was undertaken manually by AM. When analysing nuclear opacities, the nucleus was segmented from the 
anterior and posterior images of each half of the lens: the mean pixel intensity of the nucleus was then compared 
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to that of the aqueous humour (to represent background intensity level) with their ratio representing nuclear PIR. 
Cortical lens opacities were also segmented and their mean pixel intensity compared as a ratio with the back-
ground mean pixel intensity of the entire opacity-free cortex, representing cortical PIR. The area of the cortical 
opacities was also calculated as a ratio of their mean area compared to the area of the cortex. The PIR and PAR 
of posterior-subcapsular opacities were calculated in a similar manner to cortical opacities. In the DS eyes, dot 
opacities (see Fig. 1), were also visualised. These were individually identified and in addition to count, Dot PIR 
and Dot PAR were calculated. Finally, the central portion of the B-scan, covering the central 4–4.5 mm of the lens, 
was segmented in MATLAB and the proportion of dots in the central area versus the periphery was calculated.
Statistical analysis was conducted in Stata. Kruskal-Wallis rank sum test was used for comparison between 
groups as LOCS III data was non-parametric. Pixel intensity ratios were normally distributed for the control 
group, and one-away ANOVA compared group differences. To examine association, linear regression and 
Spearman rank (ρ) analysis were used, depending on normality of data.
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